Key Takeaways
- Explosive H1, driven by volume and mix: Revenue grew 135.59% YoY in H1 FY26, fueled by post-IPO capacity expansion, a richer CDMO and private label mix, and an expanded customer base.
- Margins reset during scale-up: Gross margin compressed from 23.5% to 16% and EBITDA margin to 17%, as the company absorbs product registration costs and a volume-heavy mix, with recovery promised once registrations mature.
- IPO proceeds deployed as planned: Funds have been used to upgrade manufacturing, repay borrowings, and augment working capital, directly enabling the 40% capacity increase and the ability to fulfill orders that were previously constrained.
- Regulatory approvals unlocking new markets: The Malawi cGMP approval and completed plant audits in the Philippines and Ghana are tangible steps toward diversifying export revenue, though revenue conversion from these markets is a 1-2 year process.
- What to watch next quarter: Whether the 130% YoY growth momentum is sustained into H2, any stabilization in gross margins as new product registrations begin to contribute, and concrete revenue contributions from newly entered markets like Nigeria and Malawi.
Growth Engine: Volume, Capacity & Order Book
- Volume-led surge: The 135.59% revenue jump was driven by strong volume expansion, not price, enabled by post-IPO funded capex that increased production capacity by 40%.
- Working capital unlocked growth: Post-listing, improved working capital allowed the company to offer whole sales and achieve optimum capacity utilisation, fulfilling orders that were previously lost due to capital constraints.
- Order book visibility: Management expects the same growth momentum to continue in H2 and subsequent years, citing a good order book, new countries entered, and products established over the past two years now generating revenue.
- Revenue from new capacity is unquantified: The maximum revenue the expanded capacity can yield depends entirely on product mix across five segments, and management declined to provide a specific number.
Jeet: "We are expecting the same momentum. So, it may be those figures which we are asking, but we cannot aim as of now."
Margin Reset: The Cost of Scaling
- Gross margin compression: Gross margin fell from 23.5% to 16% due to a product mix shift toward volume, plus expenses for product registration, product development, and expansion activities.
- EBITDA margin decline: EBITDA margin dropped to 17% from a historical 20%-21%, driven by growth-related expenses including product and country registration costs incurred during the scaling-up phase.
- Margin recovery mechanism: Management expects margins to improve once products are registered and can command better pricing, and is focusing on raw material optimization, vendor qualification, and bulk procurement to reduce manufacturing costs.
- Recovery has no timeline: The company is in a growing stage and will continue incurring registration expenses as it adds more products and countries, so the percentage margin will be maintained while absolute EBITDA grows.
Jeet: "Percentage we will maintain by the time, but as of now we are growing. As we are growing so we have to make many expenses as well for the old registrations and more and more products and more and more countries to cater."
Product Mix & Margin Mechanics
- Margins vary by format and geography: Tablets give higher margins, liquids give lower margins, and external preparations like ointments and creams give good margins, with the overall outcome depending on country and product mix.
- Broad mix strategy: The company does not focus on any particular therapeutic segment, instead catering to all segments based on customer demand to attract more customers.
- Branded sales as margin lever: Direct branded export sales, currently around 10% of revenue, yield significantly better margins, and the company plans to expand this once its name is established in markets through merchant exporters.
- Working capital tied to export mix: Export markets require waiting for shipments and payments, extending working capital to 185-190 days versus 140-150 days for domestic, a structural drag as the export share grows.
Harshad Rathod: "Margins are different according to the product mix. So, we are not that much clearly say the somehow product just like a tablet gives a more margin or liquid gives a little margin, less margin as compared to tablet or external preparation that ointment cream that give you the good margin."
Regulatory & Geographic Expansion
- Malawi cGMP approval secured: The approval from Malawi's pharmacy and medicines regulatory authority opens a direct export opportunity and strengthens the company's position as a CDMO partner in the African market.
- Plant registrations completed in four countries: Cambodia, Rwanda, Nigeria, and Malawi, with product registration and availability in more than 30 countries via distributors.
- Philippines and Ghana in pipeline: Plant audits have been completed in both countries, but the plant and product registration process takes 1-2 years, so near-term revenue contribution is unlikely.
- New markets entered: Nigeria and Malawi are new markets, and the company is planning to develop markets in Philippines, Ghana, and Sierra Leone.
Balance Sheet & IPO Deployment
- IPO proceeds deployed as stated: Funds were used for upgrading the manufacturing facility with new equipment and enhanced capacity, repayment of selected borrowings to strengthen the balance sheet, and augmentation of working capital to support growing orders.
- Borrowings reduced drastically: Short-term and long-term borrowings have come down significantly because the company used IPO proceeds for loan repayment as stated in the DRHP.
- Inventory elevated but supported: Inventory of ₹20 cr is considered high but is backed by 180-190 days of working capital, consistent with the export-heavy business model.
- Capital structure healthy: The company maintains a low debt-to-equity ratio and adequate liquidity to fund future expansion.
Harshad Rathod: "Going forward, our financial focus will remain on maintaining profitable growth, enhancing working capital efficiency, and ensuring consistent return ratio to prudent capital management."
Business Model & Client Profile
- Domestic is contract manufacturing only: Domestic sales, which account for 30% of revenue, are pure contract manufacturing where products carry "manufactured by Accretion Pharmaceutical Limited" and are marketed by the contract-giver, not branded sales.
- Client concentration undisclosed: Management declined to name top clients or provide a top-5 client list, citing regulatory requirements of those clients.
- No therapeutic specialization: The company does not focus on any particular therapeutic area, instead maintaining a broad product mix across antibiotics, cardiac, vitamins, and other segments to attract a wider customer base.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth momentum | Expects same momentum (130% YoY rate) to continue | H2 FY26 and subsequent years |
| Malawi export contribution | cGMP approval to contribute meaningfully to export revenues | No specific timeline |
| Philippines & Ghana market entry | Plant audits completed; registration process underway | 1-2 years for registration completion |
| EBITDA margin recovery | Return to historical 20%-21% level | Once business reaches maturity and registration expenses reduce; no date given |
| Branded sales expansion | Sell under own brand name for better margins | Once Accretion name is established in markets through merchant exporters; no date given |
| Capacity expansion revenue | 40% capacity increase completed | Revenue contribution depends on product mix; no quantification provided |
Key Metrics
| Metric | H1 FY26 |
|---|---|
| Revenue from operations (H1) | ₹43.74 cr, +135.59% YoY vs ₹18.56 cr in H1 FY25 |
| Revenue from operations (FY25 full year) | ₹57.4 cr, ~70% YoY growth |
| EBITDA (excl other income, H1) | ₹7.07 cr, +63% YoY vs ₹4.34 cr in H1 FY25 |
| EBITDA margin (H1) | 16.17%, down from ~23.5% previously; scaling expenses and product mix impact |
| EBITDA margin (FY25 full year) | ~21% |
| Profit after tax (H1) | ₹4.75 cr, +92.81% YoY vs ₹2.46 cr in H1 FY25 |
| PAT margin (H1) | 10.87% |
| PAT margin (FY25 full year) | ~12% |
| Return on capital employed (FY25) | 38% |
| IPO proceeds raised | ₹29.75 cr, deployed for capacity expansion, debt repayment, and working capital |
| Production capacity increase post-IPO | 40% |
| Export revenue share | ~70% of business |
| Domestic revenue share | ~30% of business |
| Direct export share | ~10% of total revenue |
| Working capital days (average) | 180–190 days |
| Working capital days (export) | ~185–190 days |
| Working capital days (domestic) | ~140–150 days |
| Products under registration | More than 100 across multiple countries |
| Plant registration cost per country | $15,000–$20,000 approx |
| Product registration cost per country | $2,000–$5,000 approx |
| Balance sheet size (FY24) | ~₹27 cr |
| Balance sheet size (current) | ~₹60 cr |
| Inventory | ₹20 cr |
| Revenue momentum expectation | Same growth momentum as H1 expected for upcoming periods; full-year revenue of ₹120–130 cr implied (per an analyst's math) |